This week in MedTech, new investments and strategic financing are fueling the expansion of cutting-edge healthcare solutions. From histotripsy and eye care devices to prosthetics, spinal technologies, and AI-powered health platforms, these deals are turning innovation into real-world impact. Read more below.
HistoSonics announces $250M growth financing
The company’s new ownership group – a syndicate of private and public investors that acquired a majority stake in the company for $2.25 billion in August – led the financing, along with additional investors Thiel Bio and Founders Fund, among others.
Proceeds will support ongoing commercial expansion of the Edison histotripsy system into new markets, accelerate new clinical indications throughout the body, and strengthen operational capacity for further growth.
CEO Mike Blue
Last week’s tracker: Microbot, AtaCor & more
Adagio Medical prices $50M private placement
The company said certain accredited investors agreed to purchase shares of its common stock or pre-funded warrants and accompanying common warrants.
It expects the agreement to result in approximately $19 million in upfront proceeds. Additional proceeds could reach up to approximately $31 million if investors exercise the warrants in full for cash.
President and CEO Todd Usen
Sibel Health expands Series C to $39M
The extension included several strategic investors – Maruho Co., Ltd., and Samsung Next – and builds on the company’s initial Series C round, which closed earlier this year led by The Steele Foundation for Hope with significant participation from Dräger.
This achievement demonstrates increasing trust in Sibel’s AI-driven wireless monitoring system and reinforces its goal of providing continuous, integrated, and patient-focused care.
CEO Steve Xu
ABK Biomedical raises $35 million in Series D financing
The round was led by new investor, J.P. Morgan Life Sciences Private Capital. Existing investors – F-Prime, Santé Ventures, Eight Roads Ventures, and a significant undisclosed medical device company – also participated in the round.
The proceeds of the Series D funding round will support ongoing clinical operations, prepare for the commercialisation of Eye90 microspheres, and drive further product innovation and development.
President and CEO Mike Mangano
Ottobock returns to markets with €4.2bn Frankfurt IPO as investor demand surges
German prosthetics maker Ottobock saw its shares climb 9% on debut in Frankfurt after raising €808m in Germany’s biggest IPO since March 2024.
The stock opened at €72, above the €66 offer price, giving the company a market capitalisation of €4.2bn.
CEO Oliver Jakobi
Smartlens secures $5.2m to advance FDA process and prepare for miLens launch
The round was led by Ambit Health Ventures, with participation from existing investors Graphene Ventures and Boutique Venture Partners, along with new investment from Harvard Business School Alumni Angels GNY and a group of leading eye care providers.
The financing will be used to advance the FDA clearance process and prepare for an expedited market launch following clearance.
Co-founder and CEO Savas Komban
Biomendex successfully raised $1.3 million to accelerate strategic initiatives
The funding will enable the company to advance FDA market authorizations and establish U.S. manufacturing for its innovative spine surgery solutions.
It will also support regulatory, operational, and strategic preparations as the company positions itself for an upcoming Series A financing round.
CEO Pasi Kankaanpää
ŌURA secures more than $900m for health tech advancements
The company raised funding of more than $900m, earmarked for the growth of the company’s health technology offerings. The investment, spearheaded by the Fidelity Management & Research Company, includes participation from ICONIQ, with Whale Rock and Atreides also contributing.
This influx of capital, which places its valuation at an estimated $11bn, will also be directed towards the company’s advancements in AI, refining its product offerings and broadening its distribution on an international scale.
CEO Tom Hale
